Neurogene (NGNE) – Research Analysts’ Recent Ratings Updates

A number of research firms have changed their ratings and price targets for Neurogene (NASDAQ: NGNE):

• 6/9/2026 – Neurogene had its “buy” rating reaffirmed by HC Wainwright. They now have a $70.00 price target on the stock.
• 6/3/2026 – Neurogene was given a new $70.00 price target by UBS Group AG.
• 6/3/2026 – Neurogene is now covered by Rodman & Renshaw. They set a “buy” rating and a $70.00 price target on the stock.
• 6/3/2026 – Neurogene was upgraded by Rodman & Renshaw to “strong-buy”. They now have a $70.00 price target on the stock.
• 4/28/2026 – Neurogene is now covered by Guggenheim. They set a “buy” rating and a $69.00 price target on the stock.
• 4/28/2026 – Neurogene was upgraded by Guggenheim to “strong-buy”.
• 4/21/2026 – Neurogene had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Insider Transactions at Neurogene

In other Neurogene news, CFO Christine Mikail Cvijic sold 9,600 shares of the company’s stock in a transaction dated Wednesday, May 6th. The shares were sold at an average price of $31.25, for a total value of $300,000.00. Following the completion of the sale, the chief financial officer directly owned 93,640 shares of the company’s stock, valued at approximately $2,926,250. This represents a 9.30% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Stuart Cobb sold 6,797 shares of the company’s stock in a transaction dated Friday, March 13th. The shares were sold at an average price of $20.81, for a total transaction of $141,445.57. Following the completion of the sale, the insider directly owned 30,497 shares of the company’s stock, valued at $634,642.57. The trade was a 18.23% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 20,442 shares of company stock valued at $525,622 in the last quarter. 11.68% of the stock is currently owned by insiders.

Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.